What is Humatrope?
Humatrope® (somatropin [rDNA origin] for injection) is a treatment made by Eli Lilly and Company. Humatrope is a bio-identical form of human growth hormone, produced using recombinant DNA technology. Bio-identical means that Humatrope is molecularly identical to that which is produced by the human body, it just comes from a lab rather than from the pituitary gland.
What is Humatrope used for?
Humatrope Therapy for Children and Adolescents
Humatrope is used for the treatment of conditions that are associated with pediatric and adult human growth hormone deficiency. For pediatric Patients, Humatrope is indicated for the long-term treatment of patients who have growth failure due to an inadequate secretion of normal endogenous growth hormone. Humatrope is indicated for the treatment of short stature associated with Turner syndrome in patients whose epiphyses are not closed. Humatrope helps children that have trouble growing because of human growth hormone deficiency reach their normal final adult height. Humatrope can only be used for this purpose until the epiphyseal plates have closed, because, after these structures have closed, height is essentially “locked in,” and the patient can no longer grow taller.
Beyond this point, providing HGH levels associated with childhood will lead to symptoms of acromegaly, in which the bones become thicker and wider without becoming longer. Humatrope is used for the extended treatment of idiopathic short stature, defined by height SDS ≤-2.25, and used with growth rates unlikely to achieve a normal range of adult heights, in patients whose epiphyses are not closed and for whom evaluation excludes other possible causes associated with short height stature that should be treated by other means.
Humatrope Therapy for Adults
For adult patients, Humatrope is indicated for replacement of endogenous growth hormone in adults with growth hormone deficiency. Adult Human Growth Hormone Deficiency comes in two forms: 1. Adult Onset: Patients who have growth hormone deficiency as a result of pituitary disease, radiation therapy, hypothalamic disease, surgery, or trauma. Adult onset HGH deficiency can also be the result of age related natural HGH decline, in which the body slowly loses its ability to produce sufficient HGH to meet the needs of the body after the age of thirty. 2. Childhood Onset: Patients who were HGH deficient during childhood who have growth hormone deficiency confirmed as an adult before replacement therapy with Humatrope is started. Although Humatrope only encourages growth until the end of puberty, the patient still needs human growth hormone to sustain normal cellular metabolism and can benefit from a reduced dosage of Humatrope.